Drugs / Trifluridine/Tipiracil
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03278106 | Oct 2017 → Nov 2018 | cholangiocarcinoma, gallbladder cancer | Mayo Clinic | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trifluridine/Tipiracil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03278106 ↗ |
| Route | Oral | “Patients receive trifluridine/tipiracil hydrochloride combination agent TAS-102 orally (PO)” NCT03278106 ↗ |